sub:assertion {
d:DB01222 v:identifier "DB01222" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB01222" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB01222> ;
dv:drugbank-id "APRD00442" , "DB01222" ;
dv:x-ahfs <
http://bio2rdf.org/ahfs:52:08.08> ;
dv:x-atc <
http://bio2rdf.org/atc:A07EA06> ;
dv:x-cas <
http://bio2rdf.org/cas:51333-22-3> ;
dv:x-chebi <
http://bio2rdf.org/chebi:3207> ;
dv:x-dpd <
http://bio2rdf.org/dpd:2241003> ;
dv:x-kegg <
http://bio2rdf.org/kegg:D00246> ;
dv:x-ndc <
http://bio2rdf.org/ndc:0093-6815-45> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA448681> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Budesonide> ;
dct:description "Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] The extended release oral tablet, marketed as Uceris, was FDA approved on January 14, 2013 for the management of ulcerative colitis. Budesonide is provided as a mixture of two epimers (22R and 22S). Interestingly, the 22R form is two times more active than the 22S epimer. The two forms do not interconvert."@en ;
dct:identifier "drugbank:DB01222" ;
dct:title "Budesonide"@en ;
a dv:Drug ;
rdfs:label "Budesonide [drugbank:DB01222]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB01222> , <
http://www.drugs.com/cdi/budesonide-spray.html> , <
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1621.shtml> , <
http://www.rxlist.com/cgi/generic/entocort.htm> .
}